PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.

Abstract Eribulin mesylate (eribulin) is currently used for the treatment of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms that suppress the epithelial-mesenchymal transition (EMT) of cancer cells and promote tumor vascular remodeling. In this study, we investigated the expression of markers for EMT and hypoxia in sets of clinical specimens collected before and after eribulin treatment to verify its unique mechanisms.
PMID
Related Publications

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.

Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Authors

Mayor MeshTerms
Keywords

E-cadherin

Eribulin mesylate

epithelial–mesenchymal transition

locally advanced breast cancer

metastatic breast cancer

tumor vascular remodeling

Journal Title anticancer research
Publication Year Start




PMID- 29277801
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin
      Chemotherapy for Breast Cancer.
PG  - 401-410
AB  - BACKGROUND/AIM: Eribulin mesylate (eribulin) is currently used for the treatment 
      of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent
      with unique mechanisms that suppress the epithelial-mesenchymal transition (EMT) 
      of cancer cells and promote tumor vascular remodeling. In this study, we
      investigated the expression of markers for EMT and hypoxia in sets of clinical
      specimens collected before and after eribulin treatment to verify its unique
      mechanisms. PATIENTS AND METHODS: The expression of markers for EMT and cellular 
      hypoxia [E-cadherin, N-cadherin, vimentin, and carbonic anhydrase 9 (CA9)] was
      examined immunohistochemically in MBC tissues collected from 20 patients before
      and after chemotherapy with either eribulin (n=10) or paclitaxel (n=10). RESULTS:
      An increase of E-cadherin and decrease of CA9 expression were observed in MBC
      tissues from patients with objective clinical responses to eribulin treatment.
      Patients with E-cadherin-positive conversion and CA9-negative conversion had
      significantly higher response rates (p=0.004 and p=0.024, respectively) and
      prolonged time to treatment failure (p=0.018 and p=0.038, respectively) than
      patients without changes in marker expression. CONCLUSION: Expression of EMT and 
      hypoxia markers in clinical samples from patients with MBC was suppressed by
      eribulin treatment. The results provide additional clinical data on improved
      survival of patients treated with eribulin and the mechanism of response.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kashiwagi, Shinichiro
AU  - Kashiwagi S
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan [email protected]
FAU - Asano, Yuka
AU  - Asano Y
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Goto, Wataru
AU  - Goto W
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takada, Koji
AU  - Takada K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takahashi, Katsuyuki
AU  - Takahashi K
AD  - Department of Pharmacology, Osaka City University Graduate School of Medicine,
      Osaka, Japan.
FAU - Hatano, Takaharu
AU  - Hatano T
AD  - Department of Plastic and Reconstructive Surgery, Osaka City University Graduate 
      School of Medicine, Osaka, Japan.
FAU - Tanaka, Sayaka
AU  - Tanaka S
AD  - Department of Diagnostic Pathology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takashima, Tsutomu
AU  - Takashima T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Tomita, Shuhei
AU  - Tomita S
AD  - Department of Pharmacology, Osaka City University Graduate School of Medicine,
      Osaka, Japan.
FAU - Motomura, Hisashi
AU  - Motomura H
AD  - Department of Plastic and Reconstructive Surgery, Osaka City University Graduate 
      School of Medicine, Osaka, Japan.
FAU - Ohsawa, Masahiko
AU  - Ohsawa M
AD  - Department of Diagnostic Pathology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Hirakawa, Kosei
AU  - Hirakawa K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ohira, Masaichi
AU  - Ohira M
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - E-cadherin
OT  - Eribulin mesylate
OT  - epithelial-mesenchymal transition
OT  - locally advanced breast cancer
OT  - metastatic breast cancer
OT  - tumor vascular remodeling
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2017/10/21 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/401 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):401-410.